Now Approved!
Now Approved!
Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
Delivering Innovation to the EyeTM
Focused on developing and commercializing innovative ophthalmic products and technologies for serious ophthalmic diseases
Who We Are
EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders.
Our Technology
EyePoint has developed five products approved by the FDA for, sustained-release delivery of drugs to the eye.
Our Pipeline
EyePoint has a number of products in development that utilize our proven DurasertTM and Verisome Technology platforms®.
Latest EyePoint News
- EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
- EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
- EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
- EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
- EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™